On the first days of January, our CEO, David Blánquez has been attending several events in Las Vegas and San Francisco. In Las Vegas, within the framework of CES 2020 and thanks to the European American Enterprises Council, we have had the opportunity to present our project to different investors and partners that can help us soon, supporting that our device for helping people with epilepsy can be a reality in the United States. One of the most important challenges is to obtain a certification from the American Medicines Agency, FDA, and that is where private equity assistance can help us obtain it.

During all the days of the congress, we have witnessed the latest developments that are about to surprise us in our daily lives. Above all, we have learned from new digital health projects that are coming. At mjn-neuro we believe that technology must be at the service of people and it is in this conviction that we place all our efforts to improve the quality of life of people with epilepsy.

In San Francisco, we have had an intense agenda within the framework of the immersion week organized by EAEC and Enrich USA. We have presented our project at the Berkeley business school and to the accelerators 500 startups and SFVAULT.

Finally, thanks to Acció, for their invaluable help in our daily planning to stay in the USA.

We keep going on!

Leave a Reply

L’usuari que complimenta la informació requerida al present formulari declara estar legitimat per això i es fa responsable exclusiu de la veracitat i integritat de les dades i informació que introdueix, exonerant expressament a MJN NEUROSERVEIS de qualsevol responsabilitat que es pugi generar per aquesta entitat amb ocasió de la informació facilitat a través del present formulari.

Si, accepto

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.